InDePendent: Interprofessional Dementia Care

Sponsor
German Center for Neurodegenerative Diseases (DZNE) (Other)
Overall Status
Recruiting
CT.gov ID
NCT04741932
Collaborator
University Medicine Greifswald (Other), University Medicine Rostock (Other), GNEF Gesundheitsnetz Frankfurt am Main eG (Other), Haffnet Management GmbH (Other), Demenznetzwerk Uckermark e.V. (Other), Techniker Krankenkasse (Other), AOK Nordost - Die Gesundheitskasse (Other), Federal Joint Committee (Other)
464
5
2
32.5
92.8
2.9

Study Details

Study Description

Brief Summary

Currently, around 1.7 million people with dementia live in Germany. The number of new cases per year is estimated to be around 244,000. At this time, no curative treatment for dementia exists. The progression of the disease results in high needs for care. Only a minority among People with Dementia (PwD) receive needs-based treatment and directive-compliant care. Previous studies found that more than 95% of PwD have an open need for care. The increase in chronically and multimorbid impaired patients leads to an increased number of patients in primary care. Particularly in rural regions, innovative care concepts based on a redistribution of tasks between specialized nurses and doctors could help to guarantee high-value care at all times. Nursing care can be expanded with regards to tasks and competencies, which is thought to increase the attractiveness of the nursing profession. Unfortunately, there are currently no scientific studies on the effectiveness and impact of such care concepts in Germany.

The Aim of this study is to implement a structured care concept for the reallocation of tasks between general practitioners (GPs) and nurses and to evaluate its effectiveness on the living and care situation of people with dementia living at home. "InDePendent" is a multicenter, cluster-randomized, controlled intervention study with a waiting-control group. Randomization is carried out at the level of the participating GPs in a ratio of 1:2 (intervention group : waiting-control group).

Condition or Disease Intervention/Treatment Phase
  • Other: Dementia Care Management (DCM)
N/A

Detailed Description

Previous studies found that PwD treated by primary care physicians on average have 8.8 (± 5.04; range = 0-31) unmet care needs, mainly related to nursing care (38%) and drug therapy (15%). PwD had additional needs for daily activities, social participation and showed a high level of psychological stress. The number of unmet care needs is more dependent on the physical limitations than on the cognitive impairments. The progression of dementia is therefore associated with an increase in open and unmet care needs and a reduced opportunity to recognize these needs in the primary care setting and to address them appropriately. At this time, no curative treatment for dementia exists. Thus, innovative models of high-value care have to be found in order to enable PwD to live an independent, self-determined life with a high quality of life for as long as possible. The increasing burden of disease associated with an increase in prevalence of dementia is associated with high health expenditures, which puts additional pressure on health care systems. From a health economical perspective the minimization of supply deficits and open needs of care are crucial aspects to avoid or delay a cost-intensive transfer to an inpatient facility. The overall goal of the InDePendent project is to improve the living and care situation of PwD and their relatives at home. Following this aim, an innovative redistribution of tasks between general practitioners and specialized nurses for dementia patients will be implemented and evaluated. In addition, the specialized nurses will be trained for cross-sector as well as cross-professional dementia care management (DCM), by acquisition of specific competencies to carry out medical tasks in delegation and substitution. Collaborating Dementia Networks and GP clinics will serve as the units of randomization and determine the patients' group status (control or intervention group). The GPs will systematically screen the patients for eligibility to participate in the study during routine care (eligibility criteria for screening: age ≥70 years, living at home). Patients will be screened using the validated DemTect questionnaire (eligibility for study participation: <9 points). In case of a positive screening or an existing dementia diagnosis, potential participants will receive detailed information about the study including a study-information sheet from their GP, be invited to participate and asked to provide written informed consent.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
464 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Special qualified nurses with an extended nursing role (Dementia Care Manager) record all nursing, medical, drug, psychosocial and social care needs using an IT-based care management system and then implement them over a period of six months.Special qualified nurses with an extended nursing role (Dementia Care Manager) record all nursing, medical, drug, psychosocial and social care needs using an IT-based care management system and then implement them over a period of six months.
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Interprofessional Dementia Care: Redistribution of Tasks Between Physicians and Qualified Nurses in Primary Care
Actual Study Start Date :
Jan 13, 2021
Anticipated Primary Completion Date :
Jun 30, 2022
Anticipated Study Completion Date :
Sep 30, 2023

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Care as usual

Experimental: Intervention

Other: Dementia Care Management (DCM)
A computerized "Information and Care Management System" (IMS) will identify unmet nursing, medical, psychosocial and social needs of the PwD and its informal caregiver. Based on this data, the IMS generates suggestions for interventions: The DCM in cooperation with the general practitioner (GP) develops an individual treatment and care plan that is tailored to the needs of the PwD and its caregiver. The DCM will initiate the implementation of respective actions and monitor the status of implementation. Therefore, the DCMs are supposed to take on activities that were previously usually performed by doctors (redistribution of tasks between physicians and qualified nurses in primary care).

Outcome Measures

Primary Outcome Measures

  1. Number of unmet needs (CANE) [6 months after baseline assessment]

    The CANE questionnaire (Camberwell Assessment of Need for the Elderly, Stein et al., 2019) will be used to assess participants' and their relatives' unmet needs in group comparison between IG compared to the CG. The CANE comprises 27 areas of daily life for assessing the physical, psychological, social and environmental needs of older people. There are two versions of the CANE for both participant and caregiver.

Secondary Outcome Measures

  1. Quality of life (Qol-AD) [6 months after baseline assessment]

    The Quality of life in Alzheimer's Disease (Qol-AD; Logsdon et al. 2002) will be used to assess participants' quality of life. The instrument contains 13 items. Each item is rated on a four point likert scale, in which 1 stands for being poor and 4 being excellent. Result is a sum of all 13 items from 13 to 52. Higher numbers indicate higher quality of life.

  2. Health status (EQ-5D-5L) [6 months after baseline assessment]

    The EQ-5D-5L instrument (Janssen et al. 2013) will be used to assess participants' health status, quality of life and for the health economic evaluation. The instrument contains 5 dimensions and one score from 0 to 100 to assess participants' current health status. Each of the 5 dimensions (Mobility, Self-care, Usual activities, Pain/Discomfort, Anxiety/ Depression) are rated on a five point likert scale. Result of the EQ-5D-5L is an individual health index.

  3. Costs of informal care (Resource Utilization in Dementia) [6 months after baseline assessment]

    Informal care is an essential part of society's resource consumption and the costs of dementia care. For the health economic evaluation the RUD (Resource Utilization in Dementia Questionnaire, Wimo, Jonsson & Zbrozek, 2010) will be used to determine the supply costs and the informal care provided. The RUD instrument was developed to capture the use of resources by demented patients in a clinical trial setting, which in a further step can be calculated into costs.

  4. Costs of formal care (Utilization of Medical and Nursing services) [6 months after baseline assessment]

    For the health economic evaluation the FIMA (Questionnaire for Health-Related Resource Use in an Elderly Population, Seidl et al. 2015) will be used to determine the supply costs and the formal care provided.

  5. Caregiver Burden (Zarit) [6 months after baseline assessment]

    Caregiver burden will be assessed by using the Zarit Burden Inventory (Zarit, 1980). The instrument consists of 22 items. The result of the instrument is a sum between 22 and 88 - higher results indicate a higher subjective level of burden.

Eligibility Criteria

Criteria

Ages Eligible for Study:
70 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 70+ years

  • PwD lives at home

  • existing dementia diagnosis or screening result of DemTect <9

  • caregiver: main caregiver of a PwD (Hauptversorgungsperson)

Exclusion Criteria:
  • not able to provide written consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 MEDIS Ärztenetz medizinischer Versorgung Südbrandenburg Elsterwerda Brandenburg Germany 04910
2 GNEF Gesundheitsnetz Frankfurt am Main Frankfurt Hessen Germany 60528
3 Demenz-Netzwerk Uckermark e.V. Prenzlau Mecklenburg- Western Pommerania Germany 17291
4 HaffNet Management GmbH Ueckermünde Mecklenburg- Western Pommerania Germany 17373
5 DZNE Greifswald Mecklenburg-Western-Pomerania Germany 17487

Sponsors and Collaborators

  • German Center for Neurodegenerative Diseases (DZNE)
  • University Medicine Greifswald
  • University Medicine Rostock
  • GNEF Gesundheitsnetz Frankfurt am Main eG
  • Haffnet Management GmbH
  • Demenznetzwerk Uckermark e.V.
  • Techniker Krankenkasse
  • AOK Nordost - Die Gesundheitskasse
  • Federal Joint Committee

Investigators

  • Principal Investigator: Wolfgang Hoffmann, MD, MPH, Prof., German Center for Neurodegenerative Diseases (DZNE)

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Wolfgang Hoffmann, Group Leader and Site Speaker, German Center for Neurodegenerative Diseases (DZNE)
ClinicalTrials.gov Identifier:
NCT04741932
Other Study ID Numbers:
  • 01NVF18034
First Posted:
Feb 5, 2021
Last Update Posted:
Feb 5, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Wolfgang Hoffmann, Group Leader and Site Speaker, German Center for Neurodegenerative Diseases (DZNE)
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 5, 2021